Revolutionizing Heart Health: Latest GLP-1 Data Highlights Cardiovascular Benefits
Tirzepatide Shows Promise in Reducing Cardiovascular Risk for Obese Heart Failure Patients A new analysis of the SUMMIT trial reveals that the glucagon-like peptide 1 (GLP-1) agonist tirzepatide significantly lowers the risk of cardiovascular (CV) events in patients with obesity adn heart failure with preserved ejection fraction (HFpEF). This benefit holds true regardless of whether … Read more